Acetaminophen is oxidized by human CYP1A2 to the cytotoxic metabolite N-acetylbenzoquinoneimine (NABQI). Incubation of cells transfected with human CYP1A2 (H1A2 MZ cells) with 4 -20 mM acetaminophen for 6 hours at 37°C caused extensive cytotoxicity (cell viability Ͻ10%). In contrast, nontransfected V79 MZ cells were unaffected (viability Ͼ95%). By mixing H1A2 MZ cells with V79 MZ cells in various proportions and incubating with 4 mM acetaminophen, it was shown that the NABQI released from H1A2 MZ cells also caused cytotoxicity of bystander cells. Thus, in a mixture containing 5% H1A2 MZ cells, exposure to 4 mM acetaminophen for 6 hours resulted in complete cell killing by 24 hours. A similar bystander effect was found by incubating the same proportion of CYP1A2-containing cells with ovarian tumor-derived SK-OV-3 cells or colon tumor-derived HCT116 cells. However, breast tumor-derived MDA-MB-361 cells displayed resistance to the cytotoxic effect of NABQI, and it was necessary to increase the proportion of H1A2 MZ cells to 50% to achieve complete cell killing. In conclusion, the use of acetaminophen as prodrug and CYP1A2 as an activating enzyme is a promising combination for gene-directed enzyme prodrug therapy. Cancer Gene Therapy (2000) 7, 521-525
G ene-directed enzyme prodrug therapy (GDEPT) is one of a number of approaches currently being developed for the treatment of cancer. In this approach, tumor cells are primed for increased susceptibility to a prodrug by first transfecting them with a gene encoding an enzyme capable of activating the prodrug. In this way, for example, 5-fluorocytosine can be activated by cytosine deaminase to produce the cytotoxic product 5-fluorouracil. Many other combinations of prodrug and activating enzyme have been described. 1 The treatment can be rendered specific to tumor cells by placing the gene encoding the activating enzyme under the control of a tumor-specific promoter, such as erbB-2. Thus, it is possible to limit expression of the activating enzyme to tumor cells. 2 Prodrugs for GDEPT have generally been based on conventional anti-cancer drugs, such as ifosfamide and 5-fluorocytosine, but such compounds often have limiting and serious side effects. However, any prodrug that can be enzymatically converted to a potent cytotoxic agent could be used. It is desirable that the toxic metabolite should have a limited sphere of action so that it destroys the transformed cell and its immediate bystanders but does not damage adjacent normal tissue or produce systemic toxicity. In fact, the extent of the bystander effect of the cytotoxic product is an important consideration, as tumor cells that fail to become transfected with the prodrug-activating gene can be killed in this way. Thus, it may not be necessary to transfect all tumor cells to accomplish complete tumor cell killing. Acetaminophen, which is cytotoxic through the cytochrome P450-mediated generation of a chemically reactive metabolite, N-acetylbenzoquinoneimine (NABQI), may be a suitable prodrug for use in GDEPT. The application of acetaminophen for this purpose has not been investigated previously.
Acetaminophen is a widely used and well-tolerated analgesic in therapeutic doses. Overdosage in humans and in certain susceptible species produces serious, often fatal, liver lesions. 3 Acetaminophen is largely eliminated in the liver by conjugation to form the sulfate and glucuronide derivatives. A minor pathway of metabolism is oxidation by the hepatic cytochrome P450 system to form NABQI, a chemically reactive, electrophilic species. This compound is normally detoxified by direct conjugation with reduced glutathione (GSH). However, in overdosage, sufficient NABQI is formed to deplete hepatic GSH, allowing the reactive metabolite to interact with tissue macromolecules, leading to cell death. 4 -6 In the human liver, the P450 enzymes CYP1A2, CYP3A4, and CYP2E1 catalyze the formation of NABQI; 7 however, our preliminary studies suggest that CYP1A2 is the major form involved at concentrations of acetaminophen that cause NABQI-induced toxicity. 8 Therefore, the aim of the present study was to assess the use of acetaminophen and human CYP1A2 as prodrug and activating enzyme, the extent of the bystander effect of the NABQI released from activating cells, and the susceptibility of a variety of tumor cell types to this cytotoxic agent.
MATERIALS AND METHODS

Cell culture
V79 MZ Chinese hamster cells were maintained in DulbeccoVogt's modified Eagle's medium (DMEM) supplemented with 10% fetal calf sera (FCS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin. (All tissue culture reagents were obtained from Life Technologies, Paisley, UK.) H1A2 MZ cells, which are V79 MZ cells transfected with the human CYP1A2 gene, 9 were also maintained in supplemented DMEM with the addition of geneticin at a concentration of 0.4 mg/mL. SK-OV-3 cells were grown in DMEM supplemented with 15% FCS and 2 mM L-glutamine, without the addition of antibiotics. RPMI 1640 medium with 10% FCS, 2 mM Lglutamine, 100 U/mL penicillin, and 100 g/mL streptomycin was required by the HCT116 cells. These cell lines were maintained at 37°C with 100% humidity and 5% CO 2 . MDA-MB-361 cells were grown in Leibovitz (L-15) medium supplemented with 15% FCS and 2 mM L-glutamine; they were maintained at 37°C with 100% humidity and did not require 
H1A2 MZ cells
The expression of human CYP1A2 in these cells was confirmed by measurement of 7-ethoxyresorufin O-deethylase and 7-methoxyresorufin O-deethylase activities on a cytosol-free protein fraction as described previously. 9 The respective values obtained, 5.4 Ϯ 0.1 and 12.1 Ϯ 0.2 pmol/min/mg protein (n ϭ 6), are similar to those reported previously (i.e., 6.5 and 12.8 pmol/min/mg protein), 9 and no activity was detected in the parental V79 MZ cells. Furthermore, the expression of human CYP1A2 in the cytosol-free protein fraction of H1A2 MZ cells, but not V79 MZ cells, was also demonstrated by Western blotting using an antibody specific for this P450 enzyme 10 (data not shown).
Cell viability
For cell viability experiments, 200,000 cells/well were plated onto 12-well plates (Becton Dickinson, Oxford, UK), using the medium and conditions required by the tumor cell line, and allowed to adhere overnight. Next, cells were washed with phosphate-buffered saline (PBS) before the addition of acetaminophen in 0.1 mL of PBS (concentrations of 0.1-20 mM acetaminophen were dissolved in PBS by sonication) and then maintained at 37°C. At the appropriate timepoints, cells were removed from the plates by trypsinization and collected by centrifugation. Cell viability was measured as the ability to exclude trypan blue. Cells were counted at ϫ100 magnification using an Improved Neubauer hemocytometer (Weber Scientific International, Lancing, UK); all cell counts are the mean of duplicate determinations of five fields from duplicate experiments.
RESULTS
Incubating H1A2 MZ cells, which express CYP1A2, with a range of concentrations of acetaminophen (0.1-20 mM) for 6 hours allowed the determination of cytotoxic concentrations (Fig 1) . No cytotoxicity was observed in the absence of acetaminophen or with 0.1 mM acetaminophen. However, after exposure to 1 mM acetaminophen viability fell to 62%. Incubation with 4 mM acetaminophen resulted in a further reduction in viability to 8%. Higher concentrations of acetaminophen resulted in a similar amount of cell killing (Fig 1) . In contrast, incubation of V79 MZ cells, which lack CYP1A2, with acetaminophen resulted in no loss of cell viability (Fig  1) . Therefore, as 4 mM acetaminophen was the minimum dose to give the maximum effect, this concentration was selected for further experiments.
To determine whether the toxic metabolite produced by CYP1A2 had a cytotoxic effect on bystander cells incapable of activating acetaminophen, H1A2 MZ cells were mixed with V79 MZ cells before exposure to 4 mM acetaminophen. The percentage of decline in total cell viability greatly exceeded the percentage of acetaminophen-activating cells in the mixture, indicating a significant bystander effect (Fig 2) . In the presence of 5% H1A2 MZ cells, the viability of the mixed cell population was reduced to 52%; as the proportion of H1A2 MZ cells was increased, the number of viable cells in the mixture declined (Fig 2, Table 1 ), and a near maximal effect was found with a mixture of an equal number of V79 MZ and H1A2 MZ cells (Fig 2) . In contrast, no decline in cell viability was observed in V79 MZ cells incubated in 4 mM acetaminophen or in H1A2 MZ cells incubated in PBS without acetaminophen (Fig 2, Table 1 ).
The susceptibility of tumor-derived cells to the cytotoxicity produced by the activation of acetaminophen was investigated by mixing H1A2 MZ cells with SK-OV-3, HCT116, and MDA-MB-361 cells and incubating them in the presence of 4 mM acetaminophen for 6 hours. It was found that, like V79 MZ cells, SK-OV-3 cells were highly sensitive; viability fell progressively as the proportion of H1A2 MZ cells was increased (Table  1) . HCT116 cells showed a disproportionate decrease in viability when incubated with 5% and 10% H1A2 MZ cells, although with 50% H1A2 MZ cells, the amount of cell killing could be accounted for by loss of H1A2 MZ cells alone (Table 1) . However, MDA-MB-361 cells appeared to be highly resistant to cytotoxicity, as the reduction in cell viability was similar to the proportion of H1A2 MZ cells present (Table 1) .
To determine whether the residual viable cells were programmed to die, as we have found previously, 11 attempts were made to culture the various cell types in normal growth medium after they had been exposed to acetaminophen for 6 hours in the presence of the activating H1A2 MZ cells. It was found that after 24 hours in culture, the viability of V79 MZ, SK-OV-3, and HCT116 cells mixed with as little as 5% H1A2 MZ cells fell to 0 (Table 1) . Only MDA-MB-361 cells showed resistance to cell killing, although viability was reduced to 18% even with these cells in cultures comprising an equal number of MDA-MB-361 and H1A2 MZ cells; no viable cells were found after 48 hours (Table 1) . Nevertheless, with fewer H1A2 MZ cells present, viability increased with time, presumably as the number of dividing MDA-MB-361 cells increased during culture.
DISCUSSION
Acetaminophen can be activated by the oxidation catalyzed by human CYP1A2 to form the cytotoxic compound NABQI. The combination of acetaminophen as prodrug and CYP1A2 as activating enzyme has a potential application in GDEPT. It has been demonstrated here that a sufficient amount of NABQI was produced in cells transfected with human CYP1A2 to cause cytotoxicity. Furthermore, enough NABQI is released from activating cells to cause cytotoxicity in neighboring cells. Such a bystander effect was readily demonstrated in V79 MZ cells. However, human tumor-derived cells showed a range of sensitivities. An extensive bystander effect was found using SK-OV-3 cells, an ovarian tumor-derived cell line, whereas HCT116 cells, which are derived from a colon tumor, appeared to be somewhat more resistant to the cytotoxic effect of NABQI when assessed immediately after a 6-hour incubation period. However, both of these tumor cell types appeared to have been markedly damaged by exposure to NABQI, as they failed to survive in culture. However, the MDA-MB-361 cells, which originate from a breast tumor, displayed resistance to the cytotoxic effect of NABQI, with only those cells exposed to the highest concentration being affected.
NABQI is capable of arylating and oxidizing protein thiol groups, although studies with thiol reductants such as dithiothreitol 11 and N-acetylcysteine 12 have suggested that the reversible oxidation of thiols (i.e., "oxidative stress") rather than arylation is responsible for cell death from acetaminophen. 6 Irrespective of the exact mechanism, the key factors that determine the toxicity of acetaminophen are the rate of production of NABQI, as determined by the activity of the relevant cytochrome P450 enzymes, and the starting level and extent of depletion of GSH. Thus rat liver is relatively resistant to Table 1 .
acetaminophen, but not preformed NABQI, because the rate of formation of the reactive metabolite is insufficient, even at very high concentrations of acetaminophen, to deplete GSH. 13 In contrast, hamsters are very sensitive, because acetaminophen is rapidly and extensively oxidized to NABQI. Human liver hepatocytes exhibit a range of sensitivities, which correlate with the rate of oxidation of acetaminophen to NABQI. 13 Toxicity in overdosed individuals is confined to the liver, which is the only organ that has the required level of enzyme activity to generate NABQI and deplete GSH, a prerequisite for cell damage and death. The hepatotoxicity of acetaminophen can be greatly increased in all species by prior depletion of GSH with chemicals such as diethylmaleate.
14 Thus the toxicity of acetaminophen is dependent upon the balance between the activity of the NABQI-generating enzyme and the concentration of GSH.
GSH concentrations in breast tumors (913 nmol/g tissue) are 2-fold greater than in normal breast tissue 15 but are Ͻ20% of those found in normal human liver (Ͼ5000 nmol/g tissue). Thus, if tumor cells can be made to express NABQI-producing activity similar to human liver, therapeutic doses of acetaminophen should be selectively cytotoxic to the tumor cells. Inevitably, some surrounding normal bystander cells will also be killed, although the range of this effect would be expected to be quite limited.
The present results indicate that a relatively high concentration of acetaminophen is required to kill transfected cells. Oral administration of sufficient acetaminophen to produce plasma levels in the millimolar range would carry the danger of hepatotoxicity. However, it is possible to selectively protect the liver from any toxic effects of acetaminophen by oral administration of GSH precursors such as methionine or N-acetylcysteine 16 that elevate GSH in the liver but not in other tissues. 17 Activation of acetaminophen in the liver may also be reduced by inhibition of liver P450 activity before GDEPT; for example, the mechanistic noncompetitive inhibitor of human CYP1A2, furafylline, 18 could be administered before GDEPT to eliminate hepatic CYP1A2 activity for the duration of the treatment; after plasma furafylline is cleared, the CYP1A2 activity expressed in transfected tumor cells would be unaffected. Alternatively, acetaminophen may be administered locally in the region of the tumor in which higher levels could be given with little risk of hepatotoxicity.
It might be possible to increase the efficiency of the enzyme-activating system by replacing human CYP1A2 ) , washed with PBS, and incubated with 4 mM acetaminophen in PBS for 6 hours at 37°C. The cells were then washed once with PBS and maintained for either 24 or 48 hours in culture medium appropriate to each cell type, as detailed in Materials and Methods. At 0, 6, 24, or 48 hours, the cells were washed in PBS; the viability of the mixed cell population was determined by trypan blue exclusion. The data shown are mean values Ϯ SEM of four separate determinations. Statistical significance was determined at each timepoint by comparing the viability measurements in the mixed cell populations with the viability determined both at 0 hours and in the absence of H1A2 MZ cells in the mixture in 2 ϫ 2 contingency tables using the two-tailed 2 test with Yate's correction. Viability was determined in a total of 1500 cells at each timepoint. Levels of significance are indicated as follows: **P Ͻ .001; ***P Ͻ .0001.
with another P450 enzyme with a greater capacity for acetaminophen activation. Although human CYP2E1 and CYP3A4 are known to catalyze this reaction, 7 the rates relative to CYP1A2 at high concentrations of acetaminophen have yet to be determined. Alternatively, the orthologous rodent forms of CYP1A2, CYP2E1, or CYP3A4 may provide the source of a more efficient enzyme.
In conclusion, this study has demonstrated the potential of using acetaminophen as a prodrug when combined with a cytochrome P450-mediated activation system. In future studies, the usefulness of this approach to GDEPT will need to be investigated further using in vivo models.
